Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 25
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Selbæk, Geir Aarsland, Dag Ballard, Clive Engedal, Knut Langballe, Ellen Melbye Benth, Jūratė Šaltytė and Bergh, Sverre 2016. Antipsychotic Drug Use Is Not Associated With Long-Term Mortality Risk in Norwegian Nursing Home Patients. Journal of the American Medical Directors Association, Vol. 17, Issue. 5, p. 464.e1.

    Zhai, Yaoming Yin, Song Zhang, Dongfeng and Caramelli, Paulo 2016. Association between Antipsychotic Drugs and Mortality in Older Persons with Alzheimer’s Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, Vol. 52, Issue. 2, p. 631.

    Trifiró, Gianluca Sultana, Janet and Spina, Edoardo 2014. Are the Safety Profiles of Antipsychotic Drugs Used in Dementia the Same? An Updated Review of Observational Studies. Drug Safety, Vol. 37, Issue. 7, p. 501.

    Aparasu, Rajender R. Chatterjee, Satabdi Mehta, Sandhya and Chen, Hua 2012. Risk of Death in Dual-eligible Nursing Home Residents Using Typical or Atypical Antipsychotic Agents. Medical Care, Vol. 50, Issue. 11, p. 961.

    Drye, Lea T. Ismail, Zahinoor Porsteinsson, Anton P. Rosenberg, Paul B. Weintraub, Daniel Marano, Christopher Pelton, Gregory Frangakis, Constantine Rabins, Peter V. Munro, Cynthia A. Meinert, Curtis L. Devanand, D.P. Yesavage, Jerome Mintzer, Jacobo E. Schneider, Lon S. Pollock, Bruce G. and Lyketsos, Constantine G. 2012. Citalopram for agitation in Alzheimer’s disease: Design and methods. Alzheimer's & Dementia, Vol. 8, Issue. 2, p. 121.

    Suh, Guk-Hee 2012. Drifting policies are wasting billions. International Psychogeriatrics, Vol. 24, Issue. 03, p. 343.

    Devanand, D.P. Pelton, Gregory H. Cunqueiro, Karine Sackeim, Harold A. and Marder, Karen 2011. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. International Journal of Geriatric Psychiatry, Vol. 26, Issue. 9, p. 937.

    Simoni-Wastila, Linda Ryder, Priscilla T. Qian, Jingjing Zuckerman, Ilene H. Shaffer, Thomas and Zhao, Lirong 2009. Association of Antipsychotic Use With Hospital Events and Mortality Among Medicare Beneficiaries Residing in Long-Term Care Facilities. The American Journal of Geriatric Psychiatry, Vol. 17, Issue. 5, p. 417.

    Suh, Guk-Hee 2009. The use of atypical antipsychotics in dementia: rethinking Simpson's paradox. International Psychogeriatrics, Vol. 21, Issue. 04, p. 616.

    Taipale, Heidi T. Bell, J. Simon Soini, Helena and Pitkälä, Kaisu H. 2009. Sedative Load and Mortality among Residents of Long-Term Care Facilities. Drugs & Aging, Vol. 26, Issue. 10, p. 871.

    Wolter, Dirk K. 2009. Risiken von Antipsychotika im Alter, speziell bei Demenzen 1Prof. Dr. Hans Gutzmann zum 60. Geburtstag gewidmet.. Zeitschrift für Gerontopsychologie & -psychiatrie, Vol. 22, Issue. 1, p. 17.

    Mukadam, N. Ritchie, C. W. and Sampson, E. L. 2008. Cholinesterase inhibitors for delirium: what is the evidence?. International Psychogeriatrics, Vol. 20, Issue. 02,

    OSHIMA, Norihito 2008. Beneficial and adverse effects of pharmacotherapy with risperidone on behavioral and psychological symptoms of dementia (BPSD). Psychogeriatrics, Vol. 8, Issue. 4, p. 175.

    Passmore, Michael J Gardner, David M Polak, Yvette and Rabheru, Kiran 2008. Alternatives to Atypical Antipsychotics for the Management of Dementia-Related Agitation. Drugs & Aging, Vol. 25, Issue. 5, p. 381.

    Barak, Yoram Baruch, Yehuda Mazeh, Doron Paleacu, Diana and Aizenberg, Dov 2007. Cardiac and Cerebrovascular Morbidity and Mortality Associated With Antipsychotic Medications in Elderly Psychiatric Inpatients. The American Journal of Geriatric Psychiatry, Vol. 15, Issue. 4, p. 354.

    Herrmann, Nathan Gauthier, Serge and Lysy, Paul G. 2007. Clinical practice guidelines for severe Alzheimer’s disease. Alzheimer's & Dementia, Vol. 3, Issue. 4, p. 385.

    Machado, João Carlos and Caramelli, Paulo 2007. Treatment of dementia: anything new?. Current Opinion in Internal Medicine, Vol. 6, Issue. 1, p. 85.

    Moretti, Rita Torre, Paola Antonello, Rodolfo M Vilotti, Cristina and Pizzolato, Gilberto 2007. New treatment options for vascular dementia. Aging Health, Vol. 3, Issue. 2, p. 209.

    Raivio, Minna M. Laurila, Jouko V. Strandberg, Timo E. Tilvis, Reijo S. and Pitkälä, Kaisu H. 2007. Neither Atypical Nor Conventional Antipsychotics Increase Mortality or Hospital Admissions Among Elderly Patients With Dementia: A Two-Year Prospective Study. The American Journal of Geriatric Psychiatry, Vol. 15, Issue. 5, p. 416.

    Caballero, Joshua Hitchcock, Michael Scharre, Douglas Beversdorf, David and Nahata, Milap C. 2006. Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: A retrospective study. Clinical Therapeutics, Vol. 28, Issue. 10, p. 1695.


Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home

  • Guk-Hee Suh (a1) (a2) and Ajit Shah (a2)
  • DOI:
  • Published online: 14 September 2005

Background and objectives: The use of risperidone or olanzapine to treat behavioral problems associated with dementia is no longer recommended in the U.K. because of the increased risk of cerebrovascular adverse effects (CVAEs) and/or mortality. To evaluate the risks and benefits of antipsychotics, we measured the rate of mortality in patients with dementia, Alzheimer's disease (AD) and vascular/mixed dementia and compared mortality rates between those who had received antipsychotics and those who had not received antipsychotics.

Methods: A total of 273 subjects were assessed at baseline, 6 months and 12 months using a 1-year prospective follow-up design. Mortality rates between groups were compared using a Kaplan–Meier curve and log-rank statistics. Relative risks (RRs) were examined by the Cox proportional-hazards model.

Results: The overall 1-year mortality rate in dementia was 23.8%. The mortality rate in those who had not received antipsychotics (26.8%) was higher than that in those who had received antipsychotics (20.6%). RR and 95% confidence interval (CI) of mortality, when we compared those who had not received antipsychotics with those who had received antipsychotics, was 1.277 (95% CI 1.134–1.437) after controlling for age, severity of dementia, medical comorbidities, cognitive impairment (measured by the Korean version of the Mini-mental State Examination (MMSE)) and behavioral and psychological symptoms of dementia (BPSD), measured by the Behavioral Pathology in Alzheimer's Disease Rating Scale, Korean version (BEHAVE-AD-K). When those who had not received antipsychotics were compared with those who had received both risperidone and haloperidol, RR (95% CI) was 1.225 (1.101–1.364).

Conclusion: This study does not support reports that antipsychotics increase mortality in dementia.

Corresponding author
Correspondence should be addressed to: Guk-Hee Suh, Department of Psychiatry, Hallym University College of Medicine, Hangang Sacred Heart Hospital, 94-200 Yungdungpo-Dong, 150-030 Seoul, Korea. Phone: +82 2 2639 5483; Fax: +82 2 2677 9095. Email:
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Psychogeriatrics
  • ISSN: 1041-6102
  • EISSN: 1741-203X
  • URL: /core/journals/international-psychogeriatrics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *